Skip to content
Aspeya
  • About us
  • Innovation
  • News & resources
  • Join us
  • Contact us

News & resources

Aspeya: A new name for science, insight, and innovation

March 04, 2025
March 4, 2025 Stamford, CT – March 4, 2025 – We are excited to announce that Vectura Fertin Pharma, Inc. has formally transitioned to a new corporate identity, Aspeya, Inc.

Vectura Fertin Pharma announces Agreement for Sale of Vectura Group to Molex

September 17, 2024
STAMFORD, CT—SEPT. 17, 2024—Vectura Fertin Pharma, Inc., an affiliate of Philip Morris International Inc. (PMI) (NYSE: PM), [...]

Aurora Cannabis and Vectura Fertin Pharma, Inc. announce launch of novel Luo CBD lozenge

September 09, 2024
STAMFORD, CT—SEPT. 17, 2024—Vectura Fertin Pharma, Inc., an affiliate of Philip Morris International Inc. (PMI) (NYSE: PM), [...]

Aurora Cannabis and Vectura Fertin Pharma announce commercial collaboration

August 01, 2024
STAMFORD, CT—SEPT. 17, 2024—Vectura Fertin Pharma, Inc., an affiliate of Philip Morris International Inc. (PMI) (NYSE: PM), [...]
  • About us
  • Innovation
  • News & resources
  • Join us
  • Contact us

Social media

LinkedInLinkedIn
  • Terms of use
  • Privacy Notice
  • Company information
  • Cookie preferences
© 2025 Aspeya, Inc. All rights are reserved.

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information, which may not comply with any legal process, regulation, registration or usage in the country of your origin.